Blog
RSS FeedPosted by Michael Wonder on 14 Aug 2019
Health Canada approves Tecentriq (atezolizumab), first new treatment in 20 years for aggressive form of lung cancer
13 August 2019 - Data show Tecentriq in combination with carboplatin and etoposide helped patients with extensive-stage small cell lung ...
Posted by Michael Wonder on 31 Jul 2019
Health Canada approves Vitrakvi (larotrectinib), the first tumour agnostic cancer treatment for advanced solid tumours harbouring an NTRK gene fusion
30 July 2019 - Bayer announced today that there is now a treatment in Canada for tyrosine receptor kinase fusion ...
Posted by Michael Wonder on 24 Jul 2019
Alnylam launches Onpattro (patisiran) for the treatment of polyneuropathy in hATTR amyloidosis, the first-ever RNAi therapeutic approved in Canada
23 July 2019 - Onpattro is the only treatment that demonstrated improvement, relative to baseline, in both polyneuropathy and quality ...
Posted by Michael Wonder on 17 Jul 2019
Knight Therapeutics announces Health Canada has approved Nerlynx for early-stage breast cancer
16 July 2019 - Knight Therapeutics announced today that Health Canada has approved Nerlynx (neratinib) for the extended adjuvant treatment of ...
Posted by Michael Wonder on 13 Jul 2019
Esperoct is now approved in Canada for the treatment of haemophilia A in both children and adults
12 July 2019 - New treatment can help Canadians living with haemophilia A better manage their bleeding episodes ...
Posted by Michael Wonder on 11 Jul 2019
Health Canada has authorised Vyvanse (lisdexamphetamine dimesylate), the first and only, chewable tablet for the treatment of attention deficit/hyperactivity disorder
10 July 2019 - Vyvanse offers an additional option for patients who prefer the convenience of a chewable tablet, or who ...
Posted by Michael Wonder on 11 Jul 2019
Health Canada approves Pomalyst-based triplet combination for patients with multiple myeloma
10 July 2019 - Pomalyst in combination with bortezomib and dexamethasone, provides a new medication option for patients living with multiple ...
Posted by Michael Wonder on 19 Jun 2019
Health Canada approves Hemlibra for haemophilia A patients without factor VIII inhibitors
18 June 2019 - Hemlibra is the only treatment that can be self-injected subcutaneously once weekly for patients with hemophilia A ...
Posted by Michael Wonder on 30 May 2019
Health Canada approves Tecentriq (atezolizumab) combination therapy for first-line treatment of metastatic non-squamous non-small cell lung cancer
29 May 2019 - Data show this new option can help some patients with metastatic non-small cell lung cancer live significantly ...
Posted by Michael Wonder on 30 May 2019
Janssen announces Health Canada approval of Tremfya One-Press (guselkumab) - a patient-controlled injector for adults with moderate-to-severe plaque psoriasis
29 May 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that Health Canada has approved Tremfya One-Press, ...
Posted by Michael Wonder on 23 May 2019
Health Canada approves Mylan and Biocon's Ogivri, the first trastuzumab biosimilar, for the treatment of HER2-positive breast and gastric cancers
22 May 2019 - Ogivri is a part of Mylan's robust portfolio of 20 biosimilar and insulin analog products. ...
Posted by Michael Wonder on 17 May 2019
Health Canada approves injectable hydromorphone to treat opioid addiction
16 May 2019 - Canada is first country to approve the pain drug for severe opioid use disorder, says Health ...
Posted by Michael Wonder on 09 May 2019
First and only PARP inhibitor, Lynparza (olaparib) approved as a first-line maintenance therapy treatment in BRCA mutated advanced ovarian cancer
8 May 2019 - AstraZeneca and Merck's Lynparza reduced the risk of disease progression or death by 70% compared to ...
Posted by Michael Wonder on 04 May 2019
Seattle Genetics announces progress in expanding Adcentis (brentuximab vedotin) indications in Canada
3 May 2019 - Health Canada approves Adcetris in combination with AVD chemotherapy for the treatment of previously untreated Hodgkin's lymphoma ...
Posted by Michael Wonder on 03 May 2019
Cresemba now available in Canada for the treatment of invasive aspergillosis and invasive mucormycosis
2 May 2019 - AVIR Pharma is pleased to announce that Cresemba (isavuconazole, as isavuconazonium sulphate), an anti-fungal approved for the ...